Senseonics Leads Development Efforts of a Long-Term “Artificial Pancreas” System for Use in the International Diabetes Closed Loop Trial
Three European Clinical Trial Sites Tapped to Test Closed Loop System
GERMANTOWN, Md.--(BUSINESS WIRE)--
Senseonics Holdings, Inc. (NYSE-MKT: SENS), a medical technology company
focused on the development and commercialization of transformative
glucose monitoring products, today announced a collaboration with
TypeZero Technologies, Inc., a personalized diabetes management company,
and Roche Diabetes Care, Inc., a global leader for diabetes management
systems and services, to develop a long-term automated insulin delivery
system.
The collaboration is part of the National Institutes of Health
(NIH)-funded International Diabetes Closed Loop (IDCL) Trial, which was
designed to test automated insulin delivery systems. “This partnership
is an example of how industry, research and clinical care work together
to move innovative technologies from research to development and then to
patients to minimize the burden of diabetes,” said Boris Kovatchev, PhD,
Director of the Center for Diabetes Technology at the University of
Virginia and principal investigator of the IDCL Trial.
This phase of the IDCL Trial will integrate Senseonics’ Eversense®
CGM System, a long-term, implantable continuous glucose monitoring (CGM)
system with TypeZero’s inControl AP algorithms and Roche’s Accu-Chek®
Insight Insulin Pump. The inControl software will automatically adjust
and regulate insulin delivery based on the combination of data received
from the CGM system and the insulin pump.
“The promise of automated insulin delivery systems is the ability to
automatically and sustainably maintain tight glucose control while
avoiding hypoglycemia. With this partnership, we are one step closer to
bringing this promise to market and to significantly improve the
everyday challenges of people with diabetes,” said Tim Goodnow,
President and CEO of Senseonics.
The collaboration is the first of its kind to incorporate a CGM sensor
that lasts up to 90 days with an easy and discreet insulin pump and
smart algorithms for closed loop applications. The trial will include
three clinical centers in Europe – the University of Amsterdam in the
Netherlands, the University of Padova in Italy and University Hospital
of Montpellier in France. Hans de Vries, professor of Internal Medicine
at the University of Amsterdam, believes “this is the time to focus on
developing life-enhancing technologies and systems to meet the needs of
an increasingly-connected diabetes population. My patients are ready for
these products now.”
“We have been contributing to the important research on automated
insulin delivery systems for many years. This is why we are now even
more excited to be able to build on our excellent partnerships and take
our collaboration to the next level within the IDCL Trial. We believe
this research will support us in making a true difference for people
with diabetes as we aim to improve their time in range and free them of
many daily routines,” said Marcel Gmuender, Global Head of Roche
Diabetes Care.
“Our goal has long been to bring revolutionary artificial pancreas
products to patients as quickly as possible, and our partnership with
industry pioneers like Senseonics and Roche positions us to do that,”
said Chad Rogers, CEO of TypeZero. “We are excited about delivering a
Senseonics-Roche-TypeZero solution to the IDCL Trial and, ultimately,
giving patients differentiated options for managing their type 1
diabetes.”
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the
design, development and commercialization of glucose monitoring products
designed to help people with diabetes confidently live their lives with
ease. Senseonics’ first generation continuous glucose monitoring (CGM)
system, Eversense®, includes a small sensor, smart
transmitter and mobile application. Based on fluorescence sensing
technology, the sensor is designed to be inserted subcutaneously and
communicate with the smart transmitter to wirelessly transmit glucose
levels to a mobile device. After insertion, the sensor is designed to
continually and accurately measure glucose levels. For more information
on Senseonics, please visit www.senseonics.com.
About TypeZero Technologies, Inc.
The world leader in clinically tested artificial pancreas solutions,
TypeZero Technologies is a digital health and personalized diabetes
management company dedicated to revolutionizing the treatment and
management of diabetes. TypeZero is combining next-generation data
science techniques, proven metabolic models, and modern engineering
practices to develop customized analytics tools and blood glucose
control solutions to help people with diabetes improve their health and
lives. TypeZero’s current solutions include a smartphone-based
artificial pancreas system, therapy optimization tools for health care
providers, and advisory applications for smart insulin pens. To learn
more, visit www.typezero.com.
Forward Looking Statements
Certain statements contained in this press release, other than
statements of fact that are independently verifiable at the date hereof,
may constitute “forward-looking statements.” These forward-looking
statements reflect Senseonics’ current views about its plans,
intentions, expectations, strategies and prospects, including statements
concerning the integration of the Eversense CGM System, TypeZero’s
inControl AP closed loop algorithm and Roche’s Accu-Chek Insight Insulin
Pump, the clinical development of a closed loop system in the IDCL Trial
and the potential benefits of a long-term pancreas system. Although
Senseonics believes that its plans, intentions, expectations, strategies
and prospects as reflected in or suggested by those forward-looking
statements are reasonable, Senseonics can give no assurance that the
plans, intentions, expectations or strategies will be attained or
achieved. Furthermore, actual results may differ materially from those
described in the forward-looking statements and will be affected by a
variety of risks and factors that are beyond Senseonics’ control. These
risks and uncertainties are more fully described in the section entitled
“Risk Factors” in Senseonics’ Annual Report on Form 10-K filed with the
Securities and Exchange Commission (SEC) on February 23, 2017,
Senseonics’ Quarterly Report on Form 10-Q filed with the SEC on May 4,
2017, and Senseonics’ other SEC filings. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. The
statements made in this press release speak only as of the date stated
herein, and subsequent events and developments may cause Senseonics’
expectations and beliefs to change. While Senseonics may elect to update
these forward-looking statements publicly at some point in the future,
Senseonics specifically disclaims any obligation to do so, whether as a
result of new information, future events or otherwise, except as
required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170724006210/en/
Senseonics Holdings, Inc.
R. Don Elsey, 301-556-1602
Chief
Financial Officer
[email protected]
Source: Senseonics Holdings, Inc.